Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: Brain Behav Immun. 2019 Jul 26;82:13–24. doi: 10.1016/j.bbi.2019.07.027

Figure 1.

Figure 1.

Inhibition of CD147 improves histological outcome and survival rate 28 days after stroke. A, Experimental design. tMCAO, transient middle cerebral artery occlusion; αCD147, treated with anti-CD147 antibody; isotype, treated with isotype-matched control antibody; BrdU, 5-bromo-2’-deoxyuridine; IHC, immunohistochemistry; WM, white matter. B, Representative pictures (left panel) showing whole brain atrophy and quantitative analysis (right panel) of cortical width index, n=7–14 mice per group, *p < 0.05 vs. Sham; #p < 0.05 vs. Isotype. C, Representative images (left panel) showing coronal sections (Scale bars=2 mm) stained with cresyl violet and quantitative analysis (right panel) of brain tissue loss, n=7–14 mice per group. D, Survival curves of mice in the indicated groups up to 28 days after stroke. Survived/total animals: n= 10/10 (Sham), 7/20 (isotype) and 14/20 (αCD147). *p < 0.05 vs. Sham; #p < 0.05 vs. Isotype.